Jiawei Shou

1.2k total citations · 1 hit paper
26 papers, 856 citations indexed

About

Jiawei Shou is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jiawei Shou has authored 26 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jiawei Shou's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Research Studies (6 papers) and Immunotherapy and Immune Responses (5 papers). Jiawei Shou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Research Studies (6 papers) and Immunotherapy and Immune Responses (5 papers). Jiawei Shou collaborates with scholars based in China, United States and Canada. Jiawei Shou's co-authors include Hongming Pan, Weidong Han, Liangkun You, Ju-Jun Xie, Jing Zhao, Xinbing Sui, Zhanggui Wang, Hongsen Li, Junlin Yao and Jing Jing and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Jiawei Shou

24 papers receiving 847 citations

Hit Papers

The role of STAT3 in autophagy 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The role of STAT3 in autophagy
    2015 418 citations Liangkun You, Zhanggui Wang et al. Autophagy profile →

Peers

Jiawei Shou
Liangkun You China
Lei Zhan China
Luciana Rodrigues Gomes Brazil
Xiaoxiao Zheng China
Wen-Juan Gan China
T J Collard United Kingdom
Jack Leslie United Kingdom
Angelique Onorati United States
Jianjun Tang China
Sailan Zou China
Liangkun You China
Jiawei Shou
Citations per year, relative to Jiawei Shou Jiawei Shou (= 1×) peers Liangkun You

Countries citing papers authored by Jiawei Shou

Since Specialization
Citations

This map shows the geographic impact of Jiawei Shou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiawei Shou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiawei Shou more than expected).

Fields of papers citing papers by Jiawei Shou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiawei Shou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiawei Shou. The network helps show where Jiawei Shou may publish in the future.

Co-authorship network of co-authors of Jiawei Shou

This figure shows the co-authorship network connecting the top 25 collaborators of Jiawei Shou. A scholar is included among the top collaborators of Jiawei Shou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiawei Shou. Jiawei Shou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pu, Xingxiang, Jiawei Shou, Jun Chen, et al.. (2025). Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials. Advances in Therapy. 42(7). 3249–3264.
2.
Pu, Xingxiang, Jiawei Shou, Jun Chen, et al.. (2024). Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.. Journal of Clinical Oncology. 42(16_suppl). 8062–8062. 1 indexed citations
3.
4.
Shou, Jiawei, Fan Mo, Shanshan Zhang, et al.. (2022). Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy. Frontiers in Immunology. 13. 1000681–1000681. 22 indexed citations
5.
Li, Hongsen, Jiaying Shen, Jiawei Shou, et al.. (2022). Exploring the Interobserver Agreement in Computer-Aided Radiologic Tumor Measurement and Evaluation of Tumor Response. Frontiers in Oncology. 11. 691638–691638.
6.
Wang, Jiawei, et al.. (2022). Composition of the Gut Microbiota Associated with the Response to Immunotherapy in Advanced Cancer Patients: A Chinese Real-World Pilot Study. Journal of Clinical Medicine. 11(18). 5479–5479. 11 indexed citations
7.
Jin, Sheng, Xiao Liu, Pengfei Xu, et al.. (2021). Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non–Small-Cell Lung Cancer Patients Treated With the Anti–PD-L1 Antibody. Frontiers in Molecular Biosciences. 8. 679130–679130. 13 indexed citations
8.
Jin, Rui, Ling Peng, Jiawei Shou, et al.. (2021). EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes. Frontiers in Oncology. 11. 680804–680804. 33 indexed citations
9.
Zheng, Hui, Wenchao Zhu, Hongsen Li, et al.. (2021). Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib. Frontiers in Oncology. 11. 628693–628693. 3 indexed citations
10.
Fang, Yong, Hongming Pan, Jiawei Shou, et al.. (2021). Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.. Journal of Clinical Oncology. 39(15_suppl). e21055–e21055. 2 indexed citations
11.
Pan, Hongming, Zhanggui Wang, Liming Jiang, et al.. (2020). Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Scientific Reports. 10(1). 16974–16974. 2 indexed citations
12.
Shou, Jiawei, et al.. (2020). A microRNA disease signature associated with lymph node metastasis of lung adenocarcinoma. Mathematical Biosciences & Engineering. 17(3). 2557–2568. 4 indexed citations
13.
Cai, Jingyi, Yuzi Xu, Hao Liu, et al.. (2019). Exploring the role of Mir204/211 in HNSCC by the combination of bioinformatic analysis of ceRNA and transcription factor regulation. Oral Oncology. 96. 153–160. 5 indexed citations
14.
Zhao, Rongjie, Junjie Ni, Lu Si, et al.. (2019). CircUBAP2-mediated competing endogenous RNA network modulates tumorigenesis in pancreatic adenocarcinoma. Aging. 11(19). 8484–8501. 64 indexed citations
15.
Liu, Zhen, Weiting Ge, Jiawei Shou, et al.. (2018). Analysis of potential genes and pathways associated with the colorectal normal mucosa–adenoma–carcinoma sequence. Cancer Medicine. 7(6). 2555–2566. 26 indexed citations
16.
Shou, Jiawei, Liangkun You, Junlin Yao, et al.. (2016). Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Cancer Letters. 379(1). 124–133. 50 indexed citations
17.
You, Liangkun, Zhanggui Wang, Hongsen Li, et al.. (2015). The role of STAT3 in autophagy. Autophagy. 11(5). 729–739. 418 indexed citations breakdown →
18.
Shou, Jiawei, Jing Jing, Ju-Jun Xie, et al.. (2015). Nuclear factor of activated T cells in cancer development and treatment. Cancer Letters. 361(2). 174–184. 85 indexed citations
19.
You, Liangkun, Jiawei Shou, Liming Jiang, et al.. (2015). Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget. 6(37). 40268–40282. 46 indexed citations
20.
Pan, Hongming, Zhanggui Wang, Liming Jiang, et al.. (2014). Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Scientific Reports. 4(1). 6683–6683. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liangkun You Breakdown of academic impact, for papers by Lei Zhan Breakdown of academic impact, for papers by Luciana Rodrigues Gomes Breakdown of academic impact, for papers by Xiaoxiao Zheng Breakdown of academic impact, for papers by Wen-Juan Gan Breakdown of academic impact, for papers by T J Collard Breakdown of academic impact, for papers by Jack Leslie Breakdown of academic impact, for papers by Angelique Onorati Breakdown of academic impact, for papers by Jianjun Tang Breakdown of academic impact, for papers by Sailan Zou
Rankless by CCL
2026